ADIAL PHARMACEUTICALS I-CW23 (ADILW)       0.0488  +0.01 (+31.54%)

0.0488  +0.01 (+31.54%)

ADIAL PHARMACEUTICALS I-CW230.0488

NASDAQ:ADILW (3/24/2023, 8:14:06 PM)+0.01 (+31.54%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorN/A
GICS IndustryN/A
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Ins OwnersN/A
Inst OwnersN/A
Market Cap0
SharesN/A
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts100
IPON/A N/A

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

ADILW Daily chart

Company Profile

Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It focused on the development of a therapeutic agent for the treatment of alcohol use disorder. The company's lead product consists of AD04 which is in clinical stage. Adial Pharmaceuticals Inc. is based in CHARLOTTESVILLE.

Company Info

ADIAL PHARMACEUTICALS I-CW23

ADILW News

News Image4 days ago - Adial Pharmaceuticals, IncAdial Pharmaceuticals Engages The Keswick Group to Advance Partnering Activities for the Clinical Development of AD04 for Alcohol Use Disorder

The Keswick Group is led by experienced pharmaceutical business development executive, Tony Goodman...

News Image17 days ago - Adial Pharmaceuticals, IncAdial Pharmaceuticals to Present at the 35th Annual Roth Conference on March 14th

CHARLOTTESVILLE, Va., March 08, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage...

News Image19 days ago - Adial Pharmaceuticals, IncAdial Pharmaceuticals Provides Update on Regulatory Strategy for AD04 for Treatment of Alcohol Use Disorder

Company to pursue path toward U.S. and European approvals; Type C meeting with FDA confirmed for Q2 2023; plans in place to meet with multiple European...

News Image23 days ago - Adial Pharmaceuticals, IncAdial Pharmaceuticals Schedules Business Update Conference Call

Management to provide an update on its regulatory and partnering strategy for the United States and Europe...

News Image26 days ago - Adial Pharmaceuticals, IncAdial Pharmaceuticals Announces Closing of $0.75 Million At-The-Market Registered Direct Offering

CHARLOTTESVILLE, Va., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage...

News Imagea month ago - Adial Pharmaceuticals, IncAdial Pharmaceuticals Announces Pricing of $0.75 Million At-The-Market Registered Direct Offering

CHARLOTTESVILLE, Va., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage...

ADILW Twits

Here you can normally see the latest stock twits on ADILW, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example